VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Recombinant B. abortus RB51WboA
Vaccine Information
  • Vaccine Name: Recombinant B. abortus RB51WboA
  • Target Pathogen: Brucella spp.
  • Target Disease: Brucellosis
  • Vaccine Ontology ID: VO_0000404
  • Type: Live attenuated B. abortus strain
  • Preparation: RB51WboA is a recombinant Brucella strain that complements RB51 with a functional wboA gene. Rough Brucella abortus RB51 is a stable, attenuated mutant vaccine generated strain derived from virulent strain 2308. The wboA gene in RB51 is disrupted by an IS711 element. Abrogation of the wboA gene in smooth , virulent B. abortus, B. melitensis , and B. suis results in rough , attenuated mutants which fail to produce O polysaccharide (O antigen) (Vemulapalli et al., 2000).
  • Virulence: RB51WboA is not more virulent than RB51 (Vemulapalli et al., 2000b).
Host Response

Mouse Response

  • Vaccination Protocol: Groups of 13 mice each were vaccinated by intraperitoneal (i.p.) inoculation of viable strains RB51 (3 × 10^8 CFU/mouse), RB51SOD (5 × 10^8 CFU/mouse), RB51WboA (2.5 × 10^8 CFU/mouse) and RB51SOD/WboA (2.8 × 10^8 CFU/mouse) (Vemulapalli et al., 2004).
  • Persistence: No bacteria were isolated from the strain RB51WboA- and RB51SOD/WboA vaccinated mice at the time of challenge (Vemulapalli et al., 2004).
  • Challenge Protocol: Seven weeks after vaccination, five mice from each group were challenged i.p. with 3 × 10^4 CFU/mouse of virulent B. abortus 2308, and the remaining five mice were challenged i.p. with 2.4 × 10^4 CFU/mouse of virulent B. melitensis 16 M. Two weeks after challenge, the mice were euthanized and the number of CFUs in their spleens were determined (Vemulapalli et al., 2004).
  • Efficacy: Mice vaccinated with strains RB51 and RB51SOD showed significant protection in comparison to control. Mice vaccinated with strain RB51SOD showed a significantly better protection (mean reduction in CFU/spleen = 2.9 logs) than the mice vaccinated with strain RB51 (mean reduction in CFU/spleen = 1 log) (P = 0.02). No bacteria were isolated from the strain RB51WboA- and RB51SOD/WboA vaccinated mice, indicating that these mice developed a superior immunity that prevented the infection of B. abortus 2308 (Vemulapalli et al., 2004).
References
Vemulapalli et al., 2000b: Vemulapalli R, He Y, Buccolo LS, Boyle SM, Sriranganathan N, Schurig GG. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infection and immunity. 2000 Jul; 68(7); 3927-32. [PubMed: 10858205].
Vemulapalli et al., 2004: Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Veterinary microbiology. 2004 Sep 8; 102(3-4); 237-45. [PubMed: 15327798].